New cell therapy targets Hard-to-Treat cancers in first human trial
Disease control
Recruiting now
This early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…
Phase: PHASE1 • Sponsor: Zelluna Immunotherapy AS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC